1997
DOI: 10.1201/b13780
|View full text |Cite
|
Sign up to set email alerts
|

Elements of Pharmaceutical Pricing

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

2
12
0

Year Published

2000
2000
2013
2013

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 19 publications
(14 citation statements)
references
References 0 publications
2
12
0
Order By: Relevance
“…Of the four paths mentioned in the introduction and summarized in Table 1, extensive numerical simulations have only been reported for the exchange mechanism, path 4 (Funato et al 2004;Kolassa 2004). In this section we present a brief comparison of our multiple-scattering model with alternative theories and also report some model simulations which we have performed for paths 2 and 3 (Goldreich et al 2002).…”
Section: Alt E R Nat I V E F O R M At I O N M O D E L Smentioning
confidence: 99%
“…Of the four paths mentioned in the introduction and summarized in Table 1, extensive numerical simulations have only been reported for the exchange mechanism, path 4 (Funato et al 2004;Kolassa 2004). In this section we present a brief comparison of our multiple-scattering model with alternative theories and also report some model simulations which we have performed for paths 2 and 3 (Goldreich et al 2002).…”
Section: Alt E R Nat I V E F O R M At I O N M O D E L Smentioning
confidence: 99%
“… We also considered the impact of the volume of sales of a drug on price dispersion. As noted by Kolassa (1997), pharmacies may use high selling products as loss leaders to increase the number of customers. High‐volume drugs are still sold at a price above marginal cost, but the markup may be relatively smaller.…”
mentioning
confidence: 99%
“…The value of medicine therefore lies in its ability to achieve desired therapeutic outcomes that are not available through other methods or at costs significantly lower than those of other interven- tions. 6 This notion of value -the cost of medicine to the patient -introduces an element that is beyond the scope of this paper. Suffice it to say that, for the purposes of this paper, value is predominantly concerned with the consumption of medicine.…”
Section: What Is Value?mentioning
confidence: 98%
“…Furthermore, the benefits accrued to the patients in consuming the medicine, the need for the medicine derived from the health status of the patient, and alternatives available to reach the same or similar outcomes are all directly related to the utility of medicine. 6 "Utility is indicative of the total needs satisfaction which a consumer derives from the use of a product/service within a given period." 4 It stands to reason that a patient would want to maximise the utility of a medicine by ensuring that the greatest benefit is obtained from the use of the medicine, and by matching his/her healthcare need with the best medicine available.…”
Section: What Is Value?mentioning
confidence: 99%